因药源药物化学（上海）有限公司（以下简称"药源药物"）未能实现业 绩承诺，业绩承诺方 WANG YUAN、上海源盟企业管理咨询合伙企业（有限合伙） （以下简称"上海源盟"）、上海源黎企业管理合伙企业（有限合伙）（以下简称"上 海源黎"）需对上海皓元医药股份有限公司（以下简称"公司"）进行业绩补偿。 公司以人民币 1 元的总价格回购业绩承诺方合计持有的公司股份 47,725 股，占回 购注销前公司总股本 211,609,573 股的 0.02%，并全部予以注销。 公司于 2025 年 7 月 3 日收到中国证券登记结算有限责任公司上海分公司 出具的《证券过户登记确认书》，业绩承诺方持有公司的 47,725 股股票已过户至公 司回购专用证券账户。 | 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-084 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于业绩承诺补偿股份回购注销实施结果暨 股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、 ...

皓元医药公告，因药源药物化学(上海)有限公司未能实现业绩承诺，业绩承诺方WANG YUAN、上海源 盟、上海源黎需对公司进行业绩补偿。公司以人民币1元的总价格回购业绩承诺方合计持有的公司股份 47725股，占回购注销前公司总股本2.12亿股的0.02%，并全部予以注销。公司于2025年7月3日收到中国 证券登记结算有限责任公司上海分公司出具的《证券过户登记确认书》，业绩承诺方持有公司的47725 股股票已过户至公司回购专用证券账户。本次回购的47725股股票将于2025年7月4日全部注销，公司总 股本将由2.12亿股变更为2.12亿股，注册资本由2.12亿元人民币变更为2.12亿元人民币。 ...

Core Viewpoint - The company, Haoyuan Pharmaceutical, is enhancing the competitiveness of its wholly-owned subsidiary, Anhui Haoyuan, by implementing a capital increase through debt-to-equity conversion, amounting to 400 million yuan, to alleviate financial pressure and optimize its capital structure [1][4]. Group 1: Financial Performance - In Q1 2025, Haoyuan Pharmaceutical reported revenue of 606 million yuan, a year-on-year increase of 20.05%, and a net profit of 62.38 million yuan, up 272.28% [1][5]. - For the year 2024, the company achieved revenue of 2.27 billion yuan, a growth of 20.75%, and a net profit of 202 million yuan, reflecting a 58.17% increase [5][6]. - The R&D expenses for Q1 2025 were 53.71 million yuan, accounting for 8.86% of the revenue [1]. Group 2: Debt-to-Equity Conversion Details - The capital increase will raise Anhui Haoyuan's registered capital from 400 million yuan to 800 million yuan, maintaining its status as a wholly-owned subsidiary of Haoyuan Pharmaceutical [1][4]. - This is the second instance of debt-to-equity conversion for Anhui Haoyuan, following a previous increase of 200 million yuan in March 2024 [3][4]. Group 3: Business Operations and Market Position - Haoyuan Pharmaceutical focuses on providing efficient small molecule and new molecular type drugs for the global pharmaceutical and biopharmaceutical industries, continuously enhancing its market competitiveness through product pipeline expansion and technological iteration [1][5]. - The life science reagent business generated approximately 1.5 billion yuan in revenue in 2024, accounting for about 66% of total revenue, with a gross margin of 62.21% [6]. - The company has a total of 403 generic drug projects and 892 innovative drug projects, with many in the clinical trial stages, contributing to the global innovative drug development process [6].

Core Viewpoint - The company announced that the conversion price of its convertible bonds, "Haoyuan Convertible Bonds," will remain unchanged at RMB 40.58 per share following the completion of its stock incentive plan [1][4][6] Group 1: Convertible Bond Issuance - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds totaling RMB 822.35 million, with a maturity of 6 years and an initial conversion price set at RMB 40.73 per share [1] - The bonds will be listed on the Shanghai Stock Exchange on December 19, 2024, with a total issuance of 822,350 lots (8,223,500 bonds) [1] Group 2: Stock Incentive Plan and Price Adjustment - The company completed the registration of the third vesting period of its 2022 restricted stock incentive plan on June 30, 2025, increasing its total share capital from 210,961,003 shares to 211,609,573 shares [2] - The adjustment of the conversion price is based on the company's stock incentive plan and follows specific formulas outlined in the bond issuance prospectus [3][5] Group 3: Price Adjustment Calculation - The conversion price remains unchanged at RMB 40.58 per share because the total number of shares from the stock incentive plan is relatively small compared to the total share capital [4][6] - The calculation for the conversion price adjustment was performed using the formula for new share issuance, resulting in no change to the conversion price [5][6]

Core Points - Shanghai Haoyuan Pharmaceutical Co., Ltd. issued 8.2235 million convertible bonds with a total amount of 82.235 million RMB, with a maturity of 6 years [1] - The convertible bonds, named "Haoyuan Convertible Bonds," will be listed on the Shanghai Stock Exchange starting December 19, 2024 [1] - The initial conversion price is set at 40.73 RMB per share, effective from June 4, 2025, until November 27, 2030 [2] Convertible Bond Issuance Overview - The company completed the registration procedures for the first vesting period of the 2022 restricted stock incentive plan, increasing the total share capital from 210,928,884 shares to 210,959,781 shares [2] - The conversion price of the "Haoyuan Convertible Bonds" remains unchanged at 40.73 RMB per share after the completion of the vesting [2] - The conversion price will be adjusted to 40.58 RMB per share starting May 14, 2025, due to the annual equity distribution [3] Conversion Status - From June 4, 2025, to June 30, 2025, a total of 1,222 shares were converted from the "Haoyuan Convertible Bonds," representing 0.0006% of the total shares before conversion [4] - As of June 30, 2025, the amount of unconverted bonds stands at 822.3 million RMB, accounting for 99.99% of the total issuance [5] Share Capital Changes - Following the completion of the vesting procedures, the total share capital increased to 211,609,573 shares, with 648,570 shares from the incentive plan becoming tradable on July 8, 2025 [5] Additional Information - Investors can refer to the detailed prospectus for the "Haoyuan Convertible Bonds" issued on November 26, 2024, for more information [6]

Core Viewpoint - The announcement details the results of the third vesting period of the 2022 Restricted Stock Incentive Plan and the second vesting period of the reserved portion, with a total of 648,570 shares set to be listed for trading on July 8, 2025 [1][15]. Summary by Sections Important Content Highlights - The total number of shares for this stock listing is 648,570, which is part of the equity incentive shares [1]. - The vesting registration for the third vesting period and the reserved portion's second vesting period was completed on June 30, 2025 [1]. Decision-Making Process and Disclosure - The board of directors approved the incentive plan on January 26, 2022, with independent directors and legal advisors providing their consent [2][5]. - The proposed list of incentive recipients was publicly disclosed from January 27 to February 5, 2022, with no objections received [3]. - The shareholders approved the incentive plan at a meeting on February 15, 2022 [4]. Vesting Details - For the first grant portion, 84 individuals received a total of 480,868 shares, representing 39.92% of the total granted shares [10]. - The reserved portion had 20 individuals eligible for 167,702 shares, with 50% of the reserved shares vesting [11][13]. Stock Listing and Capital Changes - The total share capital increased from 210,961,003 to 211,609,573 shares due to this vesting [14]. - The company received a total of RMB 25,553,658.00 from the incentive recipients, contributing to an increase in share capital and capital reserves [15]. Financial Impact - The basic earnings per share for Q1 2025 will be diluted due to the increase in total shares, with the net profit for the period reported at RMB 62,384,400.02 [15].

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-082 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司关于不调整可转换公司 债券"皓元转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可[2024]1289 号）同意，上海皓 元医药股份有限公司（以下简称"公司"）向不特定对象发行 82,235.00 万元的 可转换公司债券，期限 6 年，每张面值为人民币 100 元，发行数量为 822,350 手 （8,223,500 张），于 2024 年 12 月 19 日在上海证券交易所挂牌交易，债券简称 "皓元转债"，债券代码"118051"，初始转股价格为人民币 40.73 元/股，经历 次调整，截至本次转股价格调整前，"皓元转债"的转股价格为 40.58 元/股。转 股期间为 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-083 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、可转债发行上市概况 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可[2024]1289 号）同意，上海 皓元医药股份有限公司（以下简称"公司"、"本公司"）于 2024 年 11 月 28 日 向不特定对象发行 822.35 万张可转换公司债券，每张面值为人民币 100 元，发 行总额 82,235.00 万元，期限 6 年。 经上海证券交易所自律监管决定书[2024]168 号文同意，公司本次可转换公 司债券于 2024 年 12 月 19 日起在上海证券交易所上市交易，债券简称"皓元转 债"，债券代码"118051"。 根据有关规定和公司《向不特定 ...

本次股票上市流通总数为648,570股。 | 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-081 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于 2022 年限制性股票激励计划首次授予部分 第三个归属期以及预留部分第二个归属期归属结果暨 股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 648,570股，占归属前公司股本总额的 0.31%。 本次股票上市流通日期为2025 年 7 月 8 日。 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分 公司有关业务规则的规定，公司 2022 年限制性股票激励计划首次授予部分第三个 归属期以及预留部分第二个归属期于 2025 年 6 月 30 日完成归属登记手续，已收 到中国证券登记结算有限责任公司上海分公司出具的《证券变更登记证明》。现将 有关情况公告如下： ...

Group 1 - Shida Shenghua expects a net loss of 52 million to 60 million yuan for the first half of 2025, a year-on-year decrease of 236.64% to 257.66% [1] - ST Zhizhi's vice president Wang Dong resigned for personal reasons, effective immediately upon delivery of the resignation to the board [1] - Haoyuan Pharmaceutical plans to increase capital by 400 million yuan to its wholly-owned subsidiary through a debt-to-equity swap, raising the registered capital from 400 million to 800 million yuan [1] Group 2 - Longxun Co. announced that shareholders and executives plan to reduce their holdings by up to 2% of the company's shares [2] - Aijian Group confirmed it has not engaged in any stablecoin-related business as of now [3] - Yanghe Co.'s chairman Zhang Liandong resigned due to work adjustments, effective immediately [5] Group 3 - Huanwei New Materials announced a stock suspension due to the major matter that may lead to a change in control [5] - Hualing Cable recently won contracts worth 456 million yuan in the power new energy sector, accounting for 10.97% of its audited revenue for 2024 [6] - Aerospace Changfeng plans to publicly transfer 55.45% of its stake in Aerospace Boke [6] Group 4 - Suzhou Planning is planning to acquire control of Dongjin Aerospace Technology, leading to a stock suspension for up to 10 trading days [6] - Yuexiu Capital intends to increase its stake in Yuexiu Real Estate using up to 204.22 million yuan through the Hong Kong Stock Connect [6] - Baichuan Co.'s actual controller and chairman Zheng Tiejiang is under investigation and has received a detention notice [7] Group 5 - XWANDA plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [8] - ST Aowei reported a loss of approximately 25.04 million yuan in inventory due to poor storage by a third party [8] - Yian Technology plans to increase capital by 120 million yuan to its subsidiary, raising its equity stake from 60% to 72.973% [9] Group 6 - Dongli New Science's wholly-owned subsidiary was applied for bankruptcy reorganization by creditors due to insolvency [11] - Bochuang Technology changed its name to Changxin Bochuang Technology, effective July 2, 2025 [14] - Huayang Co.'s controlling shareholder received a notice of administrative penalty from the China Securities Regulatory Commission [15] Group 7 - Hangzhou Thermal Power's shareholders plan to reduce their holdings by up to 4.09% of the company's shares [16] - Guoke Military Industry's two shareholders plan to reduce their holdings by up to 1.81% of the company's shares [17] - Pangu Intelligent's seven shareholders plan to reduce their holdings by up to 1% of the company's shares [19]